201 related articles for article (PubMed ID: 19636007)
1. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis.
Laurent C; Do C; Gascoyne RD; Lamant L; Ysebaert L; Laurent G; Delsol G; Brousset P
J Clin Oncol; 2009 Sep; 27(25):4211-6. PubMed ID: 19636007
[TBL] [Abstract][Full Text] [Related]
2. ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review.
Rudzki Z; Rucińska M; Jurczak W; Skotnicki AB; Maramorosz-Kurianowicz M; Mruk A; Piróg K; Utych G; Bodzioch P; Srebro-Stariczyk M; Włodarska I; Stachura J
Pol J Pathol; 2005; 56(1):37-45. PubMed ID: 15921012
[TBL] [Abstract][Full Text] [Related]
3. Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion.
Momose S; Tamaru J; Kishi H; Mikata I; Mori M; Toyozumi Y; Itoyama S
Hum Pathol; 2009 Jan; 40(1):75-82. PubMed ID: 18755494
[TBL] [Abstract][Full Text] [Related]
4. Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma.
Espinosa I; Briones J; Bordes R; Brunet S; Martino R; Sureda A; Prat J; Sierra J
Ann Hematol; 2006 Sep; 85(9):597-603. PubMed ID: 16830142
[TBL] [Abstract][Full Text] [Related]
5. Sinusoidal CD30-positive large B-cell lymphoma: a morphologic mimic of anaplastic large cell lymphoma.
Lai R; Medeiros LJ; Dabbagh L; Formenti KS; Coupland RW
Mod Pathol; 2000 Mar; 13(3):223-8. PubMed ID: 10757332
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP
J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393
[TBL] [Abstract][Full Text] [Related]
7. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
Jerkeman M; Anderson H; Dictor M; Kvaløy S; Akerman M; Cavallin-Ståhl E;
Ann Hematol; 2004 Jul; 83(7):414-9. PubMed ID: 15085385
[TBL] [Abstract][Full Text] [Related]
8. Clinical and prognostic significance of apoptotic profile in patients with newly diagnosed nodal diffuse large B-cell lymphoma (DLBCL).
Markovic O; Marisavljevic D; Cemerikic V; Perunicic M; Savic S; Filipovic B; Mihaljevic B
Eur J Haematol; 2011 Mar; 86(3):246-55. PubMed ID: 21198858
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic impact of bone marrow involvement (BMI) and therapies in diffuse large B cell lymphoma].
Yi SH; Xu Y; Zou DH; An G; Zhao YZ; Qi JY; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):307-12. PubMed ID: 19799125
[TBL] [Abstract][Full Text] [Related]
10. Primary colonic lymphoma: an analysis of 74 cases with localized large-cell lymphoma.
Tang TC; Kuo MC; Chang H; Dunn P; Wang PN; Wu JH; Lin TL; Hung YS; Kuo TT; Shih LY
Eur J Haematol; 2011 Jul; 87(1):28-36. PubMed ID: 21535155
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous presentation on the eyelid of primary, systemic, CD30+, anaplastic lymphoma kinase (ALK)-negative, anaplastic large-cell lymphoma (ALCL).
Mencía-Gutiérrez E; Gutiérrez-Díaz E; Salamanca J; Martínez-González MA
Int J Dermatol; 2006 Jun; 45(6):766-9. PubMed ID: 16796648
[TBL] [Abstract][Full Text] [Related]
12. ALK+, CD30-, CD20- large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC).
Chikatsu N; Kojima H; Suzukawa K; Shinagawa A; Nagasawa T; Ozawa H; Yamashita Y; Mori N
Mod Pathol; 2003 Aug; 16(8):828-32. PubMed ID: 12920229
[TBL] [Abstract][Full Text] [Related]
13. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Meyer PN; Fu K; Greiner T; Smith L; Delabie J; Gascoyne R; Ott G; Rosenwald A; Braziel R; Campo E; Vose J; Lenz G; Staudt L; Chan W; Weisenburger DD
Am J Clin Pathol; 2011 Jan; 135(1):54-61. PubMed ID: 21173124
[TBL] [Abstract][Full Text] [Related]
14. Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index.
Lech-Maranda E; Bienvenu J; Broussais-Guillaumot F; Warzocha K; Michallet AS; Robak T; Coiffier B; Salles G
Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):131-41. PubMed ID: 20191326
[TBL] [Abstract][Full Text] [Related]
15. Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients.
Sar A; Perizzolo M; Stewart D; Mansoor A; Difrancesco LM; Demetrick DJ
Leuk Res; 2009 Jun; 33(6):792-7. PubMed ID: 19054557
[TBL] [Abstract][Full Text] [Related]
16. Association of CD20 levels with clinicopathological parameters and its prognostic significance for patients with DLBCL.
Suzuki Y; Yoshida T; Wang G; Togano T; Miyamoto S; Miyazaki K; Iwabuchi K; Nakayama M; Horie R; Niitsu N; Sato Y; Nakamura N
Ann Hematol; 2012 Jul; 91(7):997-1005. PubMed ID: 22249209
[TBL] [Abstract][Full Text] [Related]
17. Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Ninomiya S; Hara T; Tsurumi H; Hoshi M; Kanemura N; Goto N; Kasahara S; Shimizu M; Ito H; Saito K; Hirose Y; Yamada T; Takahashi T; Seishima M; Takami T; Moriwaki H
Ann Hematol; 2011 Apr; 90(4):409-16. PubMed ID: 20938662
[TBL] [Abstract][Full Text] [Related]
18. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS
J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797
[TBL] [Abstract][Full Text] [Related]
19. Systemic anaplastic large-cell lymphoma: results from the non-Hodgkin's lymphoma classification project.
Weisenburger DD; Anderson JR; Diebold J; Gascoyne RD; MacLennan KA; Müller-Hermelink HK; Nathwani BN; Ullrich F; Armitage JO
Am J Hematol; 2001 Jul; 67(3):172-8. PubMed ID: 11391714
[TBL] [Abstract][Full Text] [Related]
20. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
Sehn LH; Donaldson J; Chhanabhai M; Fitzgerald C; Gill K; Klasa R; MacPherson N; O'Reilly S; Spinelli JJ; Sutherland J; Wilson KS; Gascoyne RD; Connors JM
J Clin Oncol; 2005 Aug; 23(22):5027-33. PubMed ID: 15955905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
